Subtrochanteric femoral fractures in patients receiving long-term alendronate therapy: Imaging features

American Journal of Roentgenology

Volumn 194, Issue 6, 2010, Pages 1581-1586

  Chan, Sarah Shock ^a   Rosenberg, Zehava Sadka ^a   Chan, Keith ^a   Capeci, Craig ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

Alendronate; Fracture; Trauma

Indexed keywords

ALENDRONIC ACID; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; BONE RADIOGRAPHY; BONE SCINTISCANNING; CLINICAL ARTICLE; DISEASE COURSE; FEMALE; FEMUR FRACTURE; HUMAN; INTRAMEDULLARY NAILING; LONG TERM CARE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; FALLING; HIP FRACTURE; MIDDLE AGED; OSTEOPOROSIS;

ACCIDENTAL FALLS; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; FEMALE; FEMORAL FRACTURES; HIP FRACTURES; HUMANS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; OSTEOPOROSIS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 77953269616     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.09.3588     Document Type: Review

References (24)

1. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996; 348:1535-1541
2. black DM, Thompson DE, bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: Fracture Intervention Trial Research Group. J Clin Endocrinol Metab 2000; 85:4118-4124
3. bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350:1189-1199
4. Luckman SP, Hughes DE, Coxon FP, Russell RGR, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13:581-589
5. Neviaser AS, Lane JM, Lenart bA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 2008; 22:346-350
6. Kwek EbK, Goh SK, Koh JbS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy? Injury 2008; 39:224-231
7. Goh SK, Yang KY, Koh JS, et al. Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br 2007; 89:349-353 (Pubitemid 46563912)
8. Sayed-Noor AS, Sjoden GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy: a case report. Acta Orthop 2008; 79:565-567
9. Lenart bA, Lorich DG, Lane JM. Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 2008; 358:1304-1306
10. Cheung RKH, Leung KK, Lee KC, Chow TC. Sequential non-traumatic femoral shaft fractures in a patient on long-term alendronate. Hong Kong Med J 2007; 13:485-489
11. Iwamoto J, Takeda T. Insufficiency fracture of the femoral neck during osteoporosis treatment: a case report. J Orthop Sci 2002; 7:707-712 (Pubitemid 36013984)
12. Schneider JP. Should bisphosphonates be continued indefinitely? An unusual fracture in a healthy woman on long-term alendronate. Geriatrics 2006; 61:31-33
13. Capeci CM, Tejwani NC. bilateral low-energy simultaneous or sequential femur fractures in patients on long-term alendronate therapy. J Bone Joint Surg Am 2009; 91:2556-2561
14. Ruggiero SL, Mehrotra b, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004; 62:527-534
15. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007; 86:1013-1021
16. Visekruna M, Wilson D, McKiernan FE. Severely suppressed bone turnover and atypical skeletal fragility. J Clin Endocrinol Metab 2008; 93:2948-2952
17. Mashiba T, Turner CH, Hirano T, Forwood C, Johnston C, burr Db. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28:524-531 (Pubitemid 32416465)
18. Mashiba T, Mori S, burr Db, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of a dog rib. J Bone Miner Metab 2005; 23:36-42
19. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CYC. Severely suppressed bone turnover: potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90:1294-1301 (Pubitemid 40463979)
20. Armamento-Villareal R, Napoli N, Panwar V, Novack D. Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N Engl J Med 2006; 355:2048-2050 (Pubitemid 44708036)
21. Krestan C, Hojreh A. Imaging of insufficiency fractures. Eur J Radiol 2009; 71:398-405
22. Spitz DJ, Newberg AH. Imaging of stress fractures in the athlete. Radiol Clin North Am 2002; 40:313-331
23. bush LA, Chew FS. Subtrochanteric femoral insuffiency fracture in woman on bisphosphonate therapy for glucocorticoid-induced osteoporosis. Radiol Case Rep 2009; 4:1
24. bush LA, Chew FS. Subtrochanteric femoral insuffiency fracture following bisphosphonate therapy for osseous metastases. Radiol Case Rep 2008; 3:1-6